Fmr LLC Lowers Holdings in Invivyd, Inc. (NASDAQ:IVVD)

Fmr LLC cut its holdings in Invivyd, Inc. (NASDAQ:IVVD) by 12.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,320,982 shares of the company’s stock after selling 1,046,775 shares during the quarter. Fmr LLC owned 0.06% of Invivyd worth $7,467,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in IVVD. Marshall Wace LLP increased its position in shares of Invivyd by 4.2% in the second quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after buying an additional 31,992 shares in the last quarter. Acadian Asset Management LLC increased its position in Invivyd by 232.0% during the second quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock worth $745,000 after purchasing an additional 474,301 shares during the last quarter. Duquesne Family Office LLC acquired a new position in shares of Invivyd in the 2nd quarter valued at about $629,000. Renaissance Technologies LLC acquired a new position in shares of Invivyd during the 2nd quarter valued at $421,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Invivyd during the 2nd quarter valued at about $263,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on IVVD. HC Wainwright dropped their price objective on Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Morgan Stanley decreased their price target on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. Finally, D. Boral Capital reissued a “buy” rating and set a $9.00 price objective on shares of Invivyd in a research note on Thursday, November 21st. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $7.89.

Insider Transactions at Invivyd

In other Invivyd news, Director Terrance Mcguire sold 160,400 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $0.59, for a total transaction of $94,636.00. Following the completion of the sale, the director now owns 4,202,679 shares of the company’s stock, valued at $2,479,580.61. This represents a 3.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 17.90% of the company’s stock.

Invivyd Stock Performance

NASDAQ IVVD opened at $0.58 on Friday. The firm’s fifty day simple moving average is $0.84 and its 200-day simple moving average is $1.08. Invivyd, Inc. has a 1-year low of $0.57 and a 1-year high of $5.20. The company has a market capitalization of $69.37 million, a PE ratio of -0.30 and a beta of 0.53.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.